Drug Search Results
More Filters [+]


Alternative Names: trimethobenzamide, tigan
Latest Update: 2023-08-10
Latest Update Note: Clinical Trial Update

Product Description

Trimethobenzamide is an orally available, antiemetic agent used in the therapy of nausea and vomiting associated with medications and gastrointestinal, viral and other illnesses. (Sourced from: https://www.ncbi.nlm.nih.gov/books/NBK548057/)

Mechanisms of Action: CTZ Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Taiwan | Turkey | United States

Approved Indications: None

Known Adverse Events: None

Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Trimethobenzamide

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases



Trial Status


Primary Completion Date

Probability of Success

Recent News Events